Rheumatology International

, Volume 30, Issue 11, pp 1411–1416 | Cite as

Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis



Ankylosing spondylitis (AS) is a systemic inflammatory rheumatic disease characterized primarily by axial joint involvement, sacroiliitis and various extra-articular manifestations. High cardiovascular mortality in AS has led many researchers to investigate possible risk factors involved with cardiovascular disease in these patients. This review summarizes published data concerning endothelial dysfunction and atherosclerosis in patients with AS. The author discusses current limitations and problems related to a better assessment of these two possible changes in AS.


Spondylarthropathies Ankylosing Spondylitis Inflammation Biomarkers Cardiovascular disease Atherosclerosis Endothelial activation Endothelial dysfunction Arterial stiffness 


  1. 1.
    Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34:585–592CrossRefPubMedGoogle Scholar
  2. 2.
    Radford EP, Doll R, Smith PG (1977) Mortality among patients with ankylosing spondylitis not given X-ray therapy. N Engl J Med 297:572–576CrossRefPubMedGoogle Scholar
  3. 3.
    Kaprove RE, Little AH, Graham DC et al (1980) Ankylosing spondylitis: survival in men with and without radiotherapy. Arthritis Rheum 23:57–61CrossRefPubMedGoogle Scholar
  4. 4.
    Darby SC, Doll R, Gill SK et al (1987) Long term mortality after a single treatment course with X-rays in patients treated for ankylosing spondylitis. Br J Cancer 55:179–190PubMedGoogle Scholar
  5. 5.
    Lehtinen K (1993) Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 52:174–176CrossRefPubMedGoogle Scholar
  6. 6.
    Salmon JE, Roman MJ (2008) Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med 121(10 Suppl 1):S3–S8CrossRefPubMedGoogle Scholar
  7. 7.
    Pereira IA, Borba EF (2008) The role of inflammation, humoral and cell mediated autoimmunity in the pathogenesis of atherosclerosis. Swiss Med Wkly 138(37–38):534–539Google Scholar
  8. 8.
    Sattar N, McCarey DW, Capell H, McInnes IB (2003) Explaining how ‘‘high-grade’’ systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108:2957–2963CrossRefPubMedGoogle Scholar
  9. 9.
    Ross R (1999) Atherosclerosis- an inflammatory disease. N Engl J Med 340:115–126CrossRefPubMedGoogle Scholar
  10. 10.
    Wick G, Knoflach M, Xu Q (2004) Autoimmune and inflammatory mechanisms in atherosclerosis. Ann Rev Immunol 22:361–403CrossRefGoogle Scholar
  11. 11.
    Doria A, Sherer Y, Meroni PT, Schoenfeld Y (2005) Inflammation and accelerated atherosclerosis. Basic mechanisms. Rheum Dis N Am 31:355–362CrossRefGoogle Scholar
  12. 12.
    Maksimowicz-McKinnon K, Bhatt DL, Calabrese LH (2004) Recent advances in vascular inflammation: C-reactive protein and other inflammatory biomarkers. Curr Opin Rheumatol 16(1):18–24CrossRefPubMedGoogle Scholar
  13. 13.
    Hahn BH, Grossman J, Chen W, McMahon M (2007) The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 28(2–3):69–75CrossRefPubMedGoogle Scholar
  14. 14.
    Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33(11):2167–2172PubMedGoogle Scholar
  15. 15.
    Sharrett AR, Ballantyne CM, Coady SA et al (2001) Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the atherosclerosis risk in communities (ARIC) study. Circulation 104:1108–1113CrossRefPubMedGoogle Scholar
  16. 16.
    Rosenson RS (2005) Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities. Curr Opin Cardiol 20:313–317CrossRefPubMedGoogle Scholar
  17. 17.
    Rader DJ (2002) High density lipoproteins and atherosclerosis. Am J Cardiol 90(suppl):i62–i70CrossRefGoogle Scholar
  18. 18.
    Rossner S (1978) Further studies on serum lipoproteins in connective tissue diseases. Atherosclerosis 31:93–99CrossRefPubMedGoogle Scholar
  19. 19.
    Joven J, Rubies-Prat J, Ras MR, de la Figuera M, Lience E, Masdeu S (1984) High density lipoprotein cholesterol subfractions and apolipoprotein A-I in patients with rheumatoid arthritis and ankylosing spondylitis. Arhtritis Rheum 27:1199–2000CrossRefGoogle Scholar
  20. 20.
    Divecha H, Sattar N, Rumley A, Cherry L, Lowe GDO, Sturrock R (2005) Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci (Lond) 109(2):171–176CrossRefGoogle Scholar
  21. 21.
    Malesci D, Niglio A, Mennillo GA, Buono R, Valentini G, La Montagna G (2007) High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol 26(5):710–714CrossRefPubMedGoogle Scholar
  22. 22.
    van Halm VP, van Denderen JC, Peters MJ, Twisk JW, van der Paardt M, van der Horst-Bruinsma IE, van de Stadt RJ, de Koning MH, Dijkmans BA, Nurmohamed MT (2006) Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. Ann Rheum Dis 65(11):1473–1477CrossRefPubMedGoogle Scholar
  23. 23.
    Masi AT, Aldag JC, Mohan PC, Murugan TSR (1999) Determinants of significantly lower serum total cholesterol levels in ankylosing spondylitis patients than age-, gender-, and medical service-matched control patients: results of multivariate analysis. Arthritis Rheum 42(Suppl):S300Google Scholar
  24. 24.
    Masi AT, Aldag JC, Mohan PC, Murugan TSR (2000) Significantly lower serum triglyceride levels in ankylosing spondylitis patients than age-, gender-, and medical service-matched controls: results of multivariate analysis. Arthritis Rheum 43(Suppl):S104Google Scholar
  25. 25.
    Burger D, Dayer JM (2002) High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation? Autoimmun Rev 1:111–117CrossRefPubMedGoogle Scholar
  26. 26.
    Hulthe J, Fagerberg B (2002) Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study). Arterioscler Thromb Vasc Biol 22:1162–1167CrossRefPubMedGoogle Scholar
  27. 27.
    Tabas I, Williams KJ, Borén J (2007) Subendothelial lipoprotein retention as the initiating process in atherosclerosis. Update and therapeutic implications. Circulation 116:1832–1844CrossRefPubMedGoogle Scholar
  28. 28.
    Marcora S, Casanova F, Williams E et al (2006) Preliminary evidence for cachexia in patients with well established ankylosing spondylitis. Rheumatology (Oxford) 45:1385–1388CrossRefGoogle Scholar
  29. 29.
    Engvall IL, Elkan AC, Tengstrand B, Cederholm T, Brismar K, Hafstrom I (2008) Cachexia in rheumatoid arthritis is associated with inflammatory activity, physical disability, and low bioavailable insulin-like growth factor. Scand J Rheumatol 37(5):321–328CrossRefPubMedGoogle Scholar
  30. 30.
    Hennekens CH (2000) Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101:1767–1772PubMedGoogle Scholar
  31. 31.
    Luc G, Bard JM, Juhan-Vague I et al (2003) C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME study. Arterioscler Thromb Vasc Biol 23:55–1261CrossRefGoogle Scholar
  32. 32.
    Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V (2000) Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148:209–214CrossRefPubMedGoogle Scholar
  33. 33.
    Pepine CJ (1998) Clinical implications of endothelial dysfunction. Clin Cardiol 21:795–799CrossRefPubMedGoogle Scholar
  34. 34.
    Deanfield JE, Halcox JP, Rabelink TJ (2007) Endothelial function and dysfunction: testing and clinical relevance. Circulation 115(10):1285–1295PubMedGoogle Scholar
  35. 35.
    Ganz P, Vita JA (2003) Testing endothelial vasomotor function. Nitric oxide, a multipotent molecule. Circulation 108:2049–2053CrossRefPubMedGoogle Scholar
  36. 36.
    Landmesser U, Hornig B, Drexler H (2004) Endothelial function: a critical determinant in atherosclerosis? Circulation 109(suppl II):II-27–II-33CrossRefGoogle Scholar
  37. 37.
    Widlansky ME, Gokce NL, Keaney JF Jr, Vita JA (2003) The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42:1149–1160CrossRefPubMedGoogle Scholar
  38. 38.
    Langheinrich AC, Kampschulte M, Buch T, Bohle RM (2007) Vasa vasorum and atherosclerosis—Quid novi? Thromb Haemost 97(6):873–879PubMedGoogle Scholar
  39. 39.
    Amoroso A, Del Porto F, Di Monaco C, Manfredini P, Afeltra A (1997) Vascular endothelial growth factor: a key mediator of neoangiogenesis. A review. Eur Rev Med Pharmacol Sci 1:17–25PubMedGoogle Scholar
  40. 40.
    Ballara SC, Miotla JM, Paleolog EM (1999) New vessels, new approaches:angiogenesis as a therapeutic target in musculoskeletal disorders. Int J Exp Pathol 80:235–250CrossRefPubMedGoogle Scholar
  41. 41.
    Benjamin M, Toumi H, Suzuki D, Hayashi K, McGonagle D (2008) Evidence for a distinctive pattern of bone formation in enthesophytes. Ann Rheum Dis. 2008 Jul 14. [Epub ahead of print]Google Scholar
  42. 42.
    Goldberger C, Dulak J, Duftner C, Weidinger F, Falkenbach A, Schirmer M (2002) Vascular endothelial growth factor (VEGF) in ankylosing spondylitis–a pilot study. Wien Med Wochenschr 152(9–10):223–225CrossRefPubMedGoogle Scholar
  43. 43.
    Drouart M, Saas P, Billot M, Cedoz J-P, Tiberghien P, Wendling D, Toussirot É (2003) High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol 132:158–162CrossRefPubMedGoogle Scholar
  44. 44.
    Taylor HG, Weiss JB, McLaughlin B, Dawes PT (1993) Raised endothelial cell stimulating angiogenesis factor in ankylosing spondylitis. Clin Exp Rheumatol 11(5):537–539PubMedGoogle Scholar
  45. 45.
    Jones PB, Makki RJ, Weiss JB (1994) Endothelial cell stimulating angiogenesis factor–a new biological marker for disease activity in ankylosing spondylitis? Br J Rheumatol 33(4):332–335CrossRefPubMedGoogle Scholar
  46. 46.
    Karoli NA, Rebrov AP (2007) Vascular wall lesion and disorder of endothelial vasoregulating function in patients with ankylosing spondylitis. Klin Med (Mosk) 85(6):54–57Google Scholar
  47. 47.
    Poddubnyĭ DA, Rebrov AP (2007) Endothelial dysfunction in patients with Bechterew’s disease (ankylosing spondylitis). Klin Med (Mosk) 85(7):66–69Google Scholar
  48. 48.
    George F, Brisson C, Poncelet P, Laurent JC, Massot O, Arnoux D, Ambrosi P, Klein-Soyer C, Cazenave JP, Sampol J (1992) Rapid isolation of human endothelial cells from whole blood using S-Endo1 monoclonal antibody coupled to immuno-magnetic beads: demonstration of endothelial injury after angioplasty. Thromb Haemost 67:147–153PubMedGoogle Scholar
  49. 49.
    Braun J, Sieper J, Breban M, Collantes-Estevez E, Davis J, Inman R et al (2002) Anti-tumournecrosis factor alpha therapy for ankylosing spondylitis: international experience. Ann Rheum Dis 61(Suppl 3):iii51–iii60PubMedGoogle Scholar
  50. 50.
    Gratacos J, Collado A, Filella X, Sanmarti R, Canete J, Llena J et al (1994) Serum cytokines(IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a closecorrelation between serum IL-6 and disease activity and severity. Br J Rheumatol 33(10):927–931CrossRefPubMedGoogle Scholar
  51. 51.
    Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM (1999) Activation ofnitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399(6736):601–605CrossRefPubMedGoogle Scholar
  52. 52.
    Caliskan M, Erdogan D, Gullu H, Yilmaz S, Gursoy Y, Yildirir A et al (2008) Impaired coronary microvascular and left ventricular diastolic functions in patients with ankylosing spondylitis. Atherosclerosis 196(1):306–312CrossRefPubMedGoogle Scholar
  53. 53.
    Choe JY, Lee MY, Rheem I, Rhee MY, Park SH, Kim SK (2008) No differences of carotid intima-media thickness between young patients with ankylosing spondylitis and healthy controls. Joint Bone Spine 75(5):548–553CrossRefPubMedGoogle Scholar
  54. 54.
    de Jongh RT, Ijzerman RG, Serne EH, Voordouw JJ, Yudkin JS, de Waal HA et al (2006) Visceral and truncal subcutaneous adipose tissue are associated with impaired capillaryrecruitment in healthy individuals. J Clin Endocrinol Metab 91(12):5100–5106CrossRefPubMedGoogle Scholar
  55. 55.
    Ijzerman RG, Voordouw JJ, van Weissenbruch MM, Yudkin JS, Serne EH, Delemarrevande Waal HA et al (2006) TNF-alpha levels are associated with skin capillary recruitment in humans: a potential explanation for the relationship between TNF-alpha and insulin resistance. Clin Sci (Lond) 110(3):361–368CrossRefGoogle Scholar
  56. 56.
    Wofford J, Kahl F, Howard G, McKinney W, Toole J, Crouse JI (1991) Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. Arterioscler Thromb 11(6):1786–1794PubMedGoogle Scholar
  57. 57.
    Sari I, Okan T, Akar S, Cece H, Altay C, Secil M, Birlik M, Onen F, Akkoc N (2006) Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology 45:283–286CrossRefPubMedGoogle Scholar
  58. 58.
    Mathieu S, Joly H, Baron G, Tournadre A, Dubost J-J, Ristori J-M, Lusson J-R, Soubrier M (2008) Trend towards increased arterial stiffness or intima–media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology 47:1203–1207CrossRefPubMedGoogle Scholar
  59. 59.
    Pieringer H (2006) Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) 45(10):1319; author reply 1319–20. Comment on:Rheumatology (Oxford). 2006 Mar;45(3):283–286Google Scholar
  60. 60.
    Galderisi M, Cicala S, Caso P et al (2002) Coronary flow reserve andmyocardial diastolic dysfunction in arterial hypertension. AmJ Cardiol 90:860–864CrossRefGoogle Scholar
  61. 61.
    Erdogan D, Gullu H, Caliskan M et al (2005) Coronary flow reserve in dipper and non-dipper hypertensive patients. Blood Press 14:345–352CrossRefPubMedGoogle Scholar
  62. 62.
    van Eijk IC, Peters MJL, Serne EH, van der Horst-Bruinsma IE, Dijkmans BAC, Smulders YM, Nurmohamed MT (2008) Microvascular function is impaired in ankylosing spondylitis and improves after TNF blockade. Ann Rheum Dis 2008 Apr 4. [Epub ahead of print]Google Scholar
  63. 63.
    Braun J, Davis J, Dougados M, Sieper J, van der LS, van der HD (2006) First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65(3):316–320CrossRefPubMedGoogle Scholar
  64. 64.
    Rudwaleit M, Listing J, Marker-Hermann E et al (2004) Spinal mobility in early ankylosing spondylitis and in axial SpA without definite radiographic sacroillitis. Ann Rheum Dis 63(Suppl 1):400Google Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Head of Spondylarthropathies ServiceFederal University of ParanáRebouças-CuritibaBrazil
  2. 2.Graduate Program in Health SciencesPontificia Universidade Catolica do ParanaCuritibaBrazil

Personalised recommendations